Venus Remedies Ltd has informed that the filing of Patent in individual countries of selection under the national phase of PCT application for the third research product of Venus Remedies Ltd has been successfully completed in 48 countries for worldwide protection of the innovation in Patent 3 i.e. "Fixed Dose Combination of a latest generation Cephalosporin with an Aminoglycoside".

The Indian patent for this innovative solution for treatment of life threatening infections caused by multi resistant P aeruginosa or Acinetobactor species and / or MRSA was filed in December 2004 and the PCT in December 2005. The company selected 48 countries with good market potential in the National Phase of the PCT application for global patent, including entire Europe, USA, Brazil, Japan, Canada, Australia and New Zealand, where it would be registering and launching this product.

The product was launched in domestic market in October 2006 and is fast growing to be one of the leading multi-specialty, critical care brands. The potential market for this product across the globe is estimated to be around US $1.00 billion.